Extracorporeal Immunoadsorption for the Treatment of Coagulation Inhibitors

被引:20
作者
Franchini, Massimo [1 ]
Sassi, Maria
Dell'Anna, Paolo
Manzato, Franco [2 ]
Salvagno, Gian Luca [3 ]
Montagnana, Martina [3 ]
Zaffanello, Marco [4 ]
Targher, Giovanni [5 ]
Lippi, Giuseppe [3 ]
机构
[1] Univ Hosp Parma, Dept Pathol & Lab Med, Immunohematol & Transfus Ctr, Parma, Italy
[2] City Hosp Mantova, Clin Chem Lab, Mantua, Italy
[3] Univ Verona, Dept Biomed & Morphol Sci, Sect Clin Chem, I-37100 Verona, Italy
[4] Univ Verona, Dept Mother Child & Biol Genet, I-37100 Verona, Italy
[5] Univ Verona, Dept Biomed & Surg Sci, Endocrinol Sect, I-37100 Verona, Italy
关键词
Immunoadsorption; bleeding; inhibitors; hemophilia; ANTIBODY-BASED IMMUNOADSORPTION; PROTEIN-A IMMUNOADSORPTION; ACQUIRED HEMOPHILIA-A; FACTOR-VIII; TOLERANCE INDUCTION; IMMUNE TOLERANCE; ACUTE BLEEDS; MANAGEMENT; PATIENT; IGG;
D O I
10.1055/s-0029-1214150
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Extracorporeal immunoadsorption is a widely used technique for the removal of pathogenic antibodies in a variety of immunologic disorders. This procedure has been used in patients with high-titer inhibitors against coagulation factors for the temporary removal of antibodies before initiating replacement therapy to achieve hemostasis and stop acute bleeding or to cover a surgical procedure. Inhibitor removal by immunoadsorption has also been included at the onset of immune tolerance protocols in both acquired and congenital hemophilia. This article summarizes the current knowledge on the use of this technique in patients with inhibitors against coagulation factors. Overall, the published literature documents that extracorporeal immunoadsorption is a safe and useful technique for the elimination of coagulation inhibitors. However, further randomized clinical trials are needed to better assess the cost-effectiveness of such procedures.
引用
收藏
页码:76 / 80
页数:5
相关论文
共 28 条
[1]   Treatment of the bleeding inhibitor patient [J].
Astermark, J .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2003, 29 (01) :77-85
[2]   Options for treating acute bleeds in addition to bypassing agents: extracorporeal immunoadsorption, FVIII/FIX, desmopressin and antifibrinolytics [J].
Berntorp, E. .
HAEMOPHILIA, 2006, 12 :62-65
[3]   Inhibitor treatment in haemophillas A and B: Summary statement for the 2006 International Consensus Conference [J].
Berntorp, E. ;
Shapiro, A. ;
Astermark, J. ;
Blanchette, V. S. ;
Collins, P. W. ;
Dimichele, D. ;
Escuriola, C. ;
Hay, C. R. M. ;
Hoots, W. K. ;
Leissinger, C. A. ;
Negrier, C. ;
Oldenburg, J. ;
Peerlinck, K. ;
Reding, M. T. ;
Hart, C. .
HAEMOPHILIA, 2006, 12 :1-7
[4]  
BRIET E, 1994, THROMB HAEMOSTASIS, V72, P162
[5]   Immunoadsorption with single-use columns for the management of bleeding in acquired hemophilia A: A series of nine cases [J].
Brzoska, Martin ;
Krause, Manuela ;
Geiger, Helmut ;
Betz, Christoph .
JOURNAL OF CLINICAL APHERESIS, 2007, 22 (04) :233-240
[6]   Extracorporeal immunoadsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX [J].
Derfler, K .
VOX SANGUINIS, 1999, 77 :57-64
[7]   International workshop on immune tolerance induction: consensus recommendations [J].
Dimichele, D. M. ;
Hoots, W. K. ;
Pipe, S. W. ;
Rivard, G. E. ;
Santagostino, E. .
HAEMOPHILIA, 2007, 13 :1-22
[8]  
FRANCESCONI M, 1982, HAEMOSTASIS, V11, P79
[9]   Acquired hemophilia A: A concise review [J].
Franchini, M ;
Gandini, G ;
Di Paolantonio, T ;
Mariani, G .
AMERICAN JOURNAL OF HEMATOLOGY, 2005, 80 (01) :55-63
[10]   Immunioadsorption of factor VIII inhibitors [J].
Freedman, J ;
Garvey, MB .
CURRENT OPINION IN HEMATOLOGY, 2004, 11 (05) :327-333